This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NovaBay Pharmaceuticals Inc (NBY)

AMEX: Health Care

11/27/15 - 12:45:00 PM ET
  • Prev Close: 0.1499
  • Avg Vol: 325.90K
  • Shares Outstanding: 87.09M
  • Mkt Cap: 13.06M
  • Div: --
  • Div Yield: --
  • P/E: N/A
  • EPS: -0.31
NBY Day's Range
NBY 52 Week Range
NBY Business Summary
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes topical non-antibiotic antimicrobial products for the eye care market. It operates through four segments: Dermatology, Ophthalmology, Urology, and Wound Care.View NBY key stats
NovaBay Pharmaceuticals Inc - NBY - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates NovaBay Pharmaceuticals Inc as a Sell with a ratings score of D-.
Report Snippet: We rate NOVABAY PHARMACEUTICALS INC (NBY) a SELL. This is driven by multiple weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.
Rating: 1.67 out of 5, 'D-' Sell.
You can view the full analysis from the report here:
NBY Rating Report
NBY Performance as of Prev. Close
NBY EPS Performance
1-Yr Ago
2-Yrs Ago
3-Yrs Ago
NBY Percentage in these ETFs
NBY News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

NBY NovaBay Pharmaceuticals Inc

Chart of NBY

Analysts Ratings for NBY

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 1 1 1 1
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

NBY Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs